Study wrapper · #984
Elamipretide (SS-31) promotes recovery by preserving mitochondrial bioenergetics and neural remodeling after spinal cord injury.
Song Z, Ban Z, Zhao H, et al. Neurochemistry international. 2026.
DOI: 10.1016/j.neuint.2026.106171PubMed: 42082001
Editor's note
An animal study in mice with supporting cell-culture work; SS-31 is the primary intervention. Results are associative and preclinical, not evidence of benefit in humans. A reasonable data point for tracking SS-31 in neural-injury research.
Plain-language abstract
In a mouse model of spinal cord injury, SS-31 was associated with improved locomotor recovery, less tissue damage, and better mitochondrial measures.
Related coverage
Weak / none
Breaking a mitochondrial danger-STING feed-forward amplifier preserves alveolar-capillary architecture and dampens interferon-chemokine signaling in acute lung injury.
Tissue & celln=——2026
Weak / none
Mitochondrial-targeted SS-31 peptide attenuates radiation-induced cardiomyocyte senescence.
Journal of radiation researchn=——2026
Supported
Elamipretide: a mitochondria-targeting drug for Barth syndrome.
Trends in pharmacological sciencesn=——2026